Trial Profile
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708, Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 11 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results of an integrated analysis from NCT01217957, NCT01383928, NCT01335685 and NCT02046070 studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 25 Jun 2017 Results assessing long-term efficacy and safety data in patients who did not withdraw from the study (n=40), presented at the 22nd Congress of the European Haematology Association